Your browser doesn't support javascript.
loading
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok, Jacqueline H L; Hedayat, Somaieh; Zhang, Lei; Aronson, Lauren I; Mirabella, Fabio; Pawlyn, Charlotte; Bright, Michael D; Wardell, Christopher P; Keats, Jonathan J; De Billy, Emmanuel; Rye, Carl S; Chessum, Nicola E A; Jones, Keith; Morgan, Gareth J; Eccles, Suzanne A; Workman, Paul; Davies, Faith E.
Afiliación
  • Fok JHL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Hedayat S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Zhang L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Aronson LI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Mirabella F; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Pawlyn C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Bright MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Wardell CP; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Keats JJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • De Billy E; Translational Genomics Research Institute (TGen), Phoenix, Arizona.
  • Rye CS; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Chessum NEA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Jones K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Morgan GJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Eccles SA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Davies FE; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Clin Cancer Res ; 24(10): 2395-2407, 2018 05 15.
Article en En | MEDLINE | ID: mdl-29391353
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Supervivencia Celular / Factores de Transcripción del Choque Térmico / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Supervivencia Celular / Factores de Transcripción del Choque Térmico / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido